Cytotoxic effects on B lymphocytes mediated by reactive oxygen species

Current Pharmaceutical Design

Volumn 10, Issue 8, 2004, Pages 841-853

  Villamor, Neus ^a   Montserrat, Emili ^a   Colomer, Dolors ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

2 methoxyoestradiol; 4 benzodiazepine; Arsenic trioxide 1; B cells; Imexon; Lymphoprolifearative disorders; Rituximab; ROS

Indexed keywords

2 METHOXYESTRADIOL; ANTIOXIDANT; ARSENIC TRIOXIDE; ASCORBIC ACID; BENZODIAZEPINE DERIVATIVE; BZ 423; FREE RADICAL; IMEXON; REACTIVE OXYGEN METABOLITE; RITUXIMAB;

AGING; B LYMPHOCYTE; CANCER THERAPY; CARCINOGENESIS; CELL DAMAGE; CELL DEATH; CELL METABOLISM; CELL PROLIFERATION; CELL STIMULATION; ENZYME ACTIVATION; HUMAN; LYMPHOCYTOTOXICITY; MAMMAL CELL; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD20; ANTINEOPLASTIC AGENTS; ARSENICALS; B-LYMPHOCYTES; BENZODIAZEPINES; CELL DEATH; ESTRADIOL; HEXANONES; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; OXIDATIVE STRESS; OXIDES; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

EID: 1642301660     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612043452848     Document Type: Review

References (114)

1. Finkel T, Holbrook NJ. Oxidants, oxidative stress and the biology of ageing. Nature 2000; 408: 239-47.
2. Finkel T. Oxidant signals and oxidative stress. Curr Opin Cell Biol 2003; 15: 247-54.
3. Turrens JF. Superoxide production by the mitochondrial respiratory chain. Biosci Rep 1997; 17: 3-8.
4. Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 2002; 3: 1129-34.
5. Cotgreave IA, Gerdes RG. Recent trends in glutathione biochemistry - glutathione-protein interactions: A molecular link between oxidative stress and cell proliferation? Biochem Biophys Res Commun 1998; 242: 1-9.
6. Chae HZ, Kang SW, Rhee SG. Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. Methods Enzymol 1999; 300: 219-26.
7. Mates JM, Sanchez-Jimenez F. Antioxidant enzymes and their implications in pathophysiologic processes. Front Biosci 1999; 4: D339-D345.
8. Sauer H, Wartenberg M, Hescheler J. Reactive oxygen species as intracellular messengers during cell growth and differentiation. Cell Physiol Biochem 2001; 11: 173-86.
9. Burdon RH, Alliangana D, Gill V. Hydrogen peroxide and the proliferation of BHK-21 cells. Free Radic Res 1995; 23: 471-86.
10. Gupta A, Rosenberger SF, Bowden GT. Increased ROS levels contribute to elevated transcription factor and MAP kinase activities in malignantly progressed mouse keratinocyte cell lines. Carcinogenesis 1999; 20: 2063-73.
11. Finkel T. Redox-dependent signal transduction. FEBS Lett 2000; 476: 52-4.
12. Owuor ED, Kong AN. Antioxidants and oxidants regulated signal transduction pathways. Biochem Pharmacol 2002; 64: 765-70.
13. Jaattela M. Programmed cell death: Many ways for cells to die decently. Ann Med 2002; 34: 480-8.
14. Salvesen GS. Caspases and apoptosis. Essays Biochem 2002; 38: 9-19.
15. Hengartner MO. The biochemistry of apoptosis. Nature 2000; 407: 770-6.
16. Fadeel B, Ahlin A, Henter JI, Orrenius S, Hampton MB. Involvement of caspases in neutrophil apoptosis: Regulation by reactive oxygen species. Blood 1998; 92: 4808-18.
17. Hampton MB, Fadeel B, Orrenius S. Redox regulation of the caspases during apoptosis. Ann N Y Acad Sci 1998; 854: 328-35.
18. Mannick JB, Schonhoff C, Papeta N, Ghafourifar P, Szibor M, Fang K, et al. S-Nitrosylation of mitochondrial caspases. J Cell Biol 2001; 154: 1111-6.
19. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: Integrating mammalian biology. Cell 2001; 104: 487-501.
20. Zou H, Yang R, Hao J, Wang J, Sun C, Fesik SW, et al. Regulation of the Apaf-1/caspase-9 apoptosome by caspase-3 and XIAP. J Biol Chem 2003; 278: 8091-8.
21. Hegde R, Srinivasula SM, Zhang Z, Wassell R, Mukattash R, Cilenti L, et al. Identification of Omi/HtrA2 as a mitochondrial apoptotic serine protease that disrupts inhibitor of apoptosis protein-caspase interaction. J Biol Chem 2002; 277: 432-8.
22. Salvesen GS, Duckett CS. IAP proteins: Blocking the road to death's door. Nat Rev Mol Cell Biol 2002; 3: 401-10.
23. Borner C. The Bcl-2 protein family: Sensors and checkpoints for life-or-death decisions. Mol Immunol 2003; 39: 615-47.
24. Cory S, Adams JM. The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer 2002; 2: 647-56.
25. Lockshin RA, Zakeri Z. Caspase-independent cell deaths. Curr Opin Cell Biol 2002; 14: 727-33.
26. Leist M, Jaattela M. Four deaths and a funeral: From caspases to alternative mechanisms. Nat Rev Mol Cell Biol 2001; 2: 589-98.
27. Schulze-Osthoff K, Krammer PH, Droge W. Divergent signalling via APO-1/Fas and the TNF receptor, two homologous molecules involved in physiological cell death. EMBO J 1994; 13: 4587-96.
28. Vercammen D, Brouckaert G, Denecker G, Van de CM, Declercq W, Fiers W, et al. Dual signaling of the Fas receptor: Initiation of both apoptotic and necrotic cell death pathways. J Exp Med 1998; 188: 919-30.
29. Ha HC, Snyder SH. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc Natl Acad Sci USA 1999; 96: 13978-82.
30. Saeki K, Yuo A, Okuma E, Yazaki Y, Susin SA, Kroemer G, et al. Bcl-2 down-regulation causes autophagy in a caspase-independent manner in human leukemic HL60 cells. Cell Death Differ 2000; 7: 1263-9.
31. Holler N, Zaru R, Micheau O, Thome M, Attinger A, Valitutti S, et al. Fas triggers an alternative, caspase-8-independent cell death pathway using the kinase RIP as effector molecule. Nat Immunol 2000; 1: 489-95.
32. Denecker G, Vercammen D, Steemans M, Vanden Berghe T, Brouckaert G, Van Loo G, et al. Death receptor-induced apoptotic and necrotic cell death: Differential role of caspases and mitochondria. Cell Death Differ 2001; 8: 829-40.
33. Martindale JL, Holbrook NJ. Cellular response to oxidative stress: Signaling for suicide and survival. J Cell Physiol 2002; 192: 1-15.
34. Fleury C, Mignotte B, Vayssiere JL. Mitochondrial reactive oxygen species in cell death signaling. Biochimie 2002; 84: 131-41.
35. Hampton MB, Orrenius S. Dual regulation of caspaseactivity by hydrogen peroxide: Implications for apoptosis. FEBS Lett 1997; 414: 552-6.
36. Armstrong JS, Steinauer KK, Hornung B, Irish JM, Lecane P, Birrell GW, et al. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ 2002; 9: 252-63.
37. Carmody RJ, Cotter TG. Signalling apoptosis: A radical approach. Redox Rep 2001; 6: 77-90.
38. Fernandez-Checa JC. Redox regulation and signaling lipids in mitochondrial apoptosis. Biochem Biophys Res Commun 2003; 304: 471-9.
39. Bai J, Cederbaum AI. Catalase protects HepG2 cells from apoptosis induced by DNA-damaging agents by accelerating the degradation of p53. J Biol Chem 2003; 278: 4660-7.
40. Bai J, Cederbaum AI. Mitochondrial catalase and oxidative injury. Biol Signals Recept 2001; 10: 189-99.
41. Tome ME, Baker AF, Powis G, Payne CM, Briehl MM. Catalase-overexpressing thymocytes are resistant to glucocorticoid-induced apoptosis and exhibit increased net tumor growth. Cancer Res 2001; 61: 2766-73.
42. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, Korsmeyer SJ. Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 1993; 75: 241-51.
43. Saitoh Y, Ouchida R, Kayasuga A, Miwa N. Anti-apoptotic defense of bcl-2 gene against hydroperoxide-induced cytotoxicity together with suppressed lipid peroxidation, enhanced ascorbate uptake, and upregulated Bcl-2 protein. J Cell Biochem 2003; 89: 321-34.
44. Nomura K, Imai H, Koumura T, Nakagawa Y. Involvement of mitochondrial phospholipid hydroperoxide glutathione peroxidase as an antiapoptotic factor, Biol Signals Recept 2001; 10: 81-92.
45. Wood ZA, Poole LB, Karplus PA. Peroxiredoxin evolution and the regulation of hydrogen peroxide signaling. Science 2003; 300: 650-3.
46. Weitsman GE, Ravid A, Liberman UA, Koren R. Vitamin D enhances caspase-dependent and -independent TNFalpha-induced breast cancer cell death: The role of reactive oxygen species and mitochondria. Int J Cancer 2003; 106: 178-86.
47. Maianski NA, Roos D, Kuijpers TW. Tumor necrosis factor alpha induces a caspase-independent death pathway in human neutrophils. Blood 2003; 101: 1987-95.
48. Garcia-Ruiz C, Colell A, Mari M, Morales A, Fernandez-Checa JC. Direct effect of ceramide on the mitochondrial electron transport chain leads to generation of reactive oxygen species. Role of mitochondrial glutathione. J Biol Chem 1997; 272: 11369-77.
49. Torres-Roca JF, Tung JW, Greenwald DR, Brown JM, Herzenberg LA, Herzenberg LA, et al. An early oxygen-dependent step is required for dexamethasone-induced apoptosis of immature mouse thymocytes. J Immunol 2000; 165: 4822-30.
50. Heck DE, Vetrano AM, Mariano TM, Laskin JD. UVB light stimulates production of reactive oxygen species: Unexpected role for catalase. J Biol Chem 2003; 278: 22432-6.
51. Wong GH. Protective roles of cytokines against radiation: induction of mitochondrial MnSOD. Biochim Biophys Acta 1995; 1271: 205-9.
52. Shacter E, Williams JA, Hinson RM, Senturker S, Lee YJ. Oxidative stress interferes with cancer chemotherapy: Inhibition of lymphoma cell apoptosis and phagocytosis. Blood 2000; 96: 307-13.
53. Kurosaki T. Molecular dissection of B cell antigen receptor signaling. Int J Mol Med 1998; 1: 515-27.
54. Healy JI, Goodnow CC. Positive versus negative signaling by lymphocyte antigen receptors. Annu Rev Immunol 1998; 16: 645-70.
55. Ding J, Takano T, Gao S, Han W, Noda C, Yanagi S, et al. Syk is required for the activation of Akt survival pathway in B cells exposed to oxidative stress. J Biol Chem 2000; 275: 30873-7.
56. Xu D, Rovira II, Finkel T. Oxidants painting the cysteine chapel: Redox regulation of PTPs. Dev Cell 2002; 2: 251-2.
57. Babior BM, Lambeth JD, Nauseef W. The neutrophil NADPH oxidase. Arch Biochem Biophys 2002; 397: 342-4.
58. Hasbold J, Klaus GG. Anti-immunoglobulin antibodies induce apoptosis in immature B cell lymphomas. Eur J Immunol 1990; 20: 1685-90.
59. Hibner U, Benhamou LE, Haury M, Cazenave PA, Sarthou P. Signaling of programmed cell death induction in WEHI-231 B lymphoma cells. Eur J Immunol 1993; 23: 2821-5.
60. Gordon J, Pound JD. Fortifying B cells with CD154: An engaging tale of many hues. Immunology 2000; 100: 269-80.
61. Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kappa B transcription factor and HIV-1. EMBO J 1991; 10: 2247-58.
62. Hamano T, Iwasaki T, Ogata A, Hashimoto N, Kakishita E. The molecular mechanism in activation-induced cell death of an Ag-reactive B cell clone. Clin Exp Immunol 2002; 128: 436-43.
63. Stolte M, Bayerdorffer E, Morgner A, Alpen B, Wundisch T, Thiede C, et al. Helicobacter and gastric MALT lymphoma. Gut 2002; 50 Suppl 3:III19-III24.
64. Bagchi D, McGinn TR, Ye X, Bagchi M, Krohn RL, Chatterjee A, et al. Helicobacter pylori-induced oxidative stress and DNA damage in a primary culture of human gastric mucosal cells. Dig Dis Sci 2002; 47: 1405-12.
65. Rollinson S, Levene AP, Mensah FK, Roddam PL, Allan JM, Diss TC, et al. Gastric marginal zone lymphoma is associated with polymorphisms in genes involved in inflammatory response and antioxidative capacity. Blood 2003; 102: 1007.
66. Nakamura S, Matsumoto T, Nakamura S, Jo Y, Fujisawa K, Suekane H, et al. Chromosomal translocation t(11; 18)(q21;q21) in gastrointestinal mucosa associated lymphoid tissue lymphoma. J Clin Pathol 2003; 56: 36-42.
67. Ye H, Liu H, Attygalle A, Wotherspoon AC, Nicholson AG, Charlotte F, et al. Variable frequencies of t(11;18)(q21;q21) in MALT lymphomas of different sites: Significant association with CagA strains of H. pylori in gastric MALT lymphoma. Blood 2003; 102: 1012.
68. Moran EC, Kamiguti AS, Cawley JC, Pettitt AR. Cytoprotective antioxidant activity of serum albumin and autocrine catalase in chronic lymphocytic leukaemia. Br J Haematol 2002; 116: 316-28.
69. Cha MK, Kim IH. Glutathione-linked thiol peroxidase activity of human serum albumin: A possible antioxidant role of serum albumin in blood plasma. Biochem Biophys Res Common 1996; 222: 619-25.
70. Halliwell B, Jenner P. Impaired clearance of oxidised proteins in neurodegenerative diseases. Lancet 1998; 351: 1510.
71. Iglesias J, Abernethy VE, Wang Z, Lieberthal W, Koh JS, Levine JS. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am J Physiol 1999; 277: F711-22.
72. Jones DT, Ganeshaguru K, Anderson RJ, Jackson TR, Bruckdorfer KR, Low SY, et al. Albumin activates the AKT signaling pathway and protects B-chronic lymphocytic leukemia cells from chlorambucil- and radiation- induced apoptosis. Blood 2003; 101: 3174-80.
73. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R, et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
74. Hiddemann W, Dreyling M, Unterhalt M. Rituximab plus chemotherapy in follicular and mantle cell lymphomas. Semin Oncol 2003; 30: 16-20.
75. Kosmas C, Stamatopoulos K, Stavroyianni N, Tsavaris N, Papadaki T. Anti-CD20-based therapy of B cell lymphoma: State of the art. Leukemia 2002; 16: 2004-15.
76. Montserrat E. Rituximab in chronic lymphocytic leukemia. Semin Oncol 2003; 30: 34-9.
77. Munshi NC, Barlogie B. Role for high-dose therapy with autologous hematopoietic stem cell support in Waldenstrom's macroglobulinemia. Semin Oncol 2003; 30: 282-5.
78. Stashenko P, Nadler LM, Hardy R, Schlossman SF. Characterization of a human B lymphocyte-specific antigen. J Immunol 1980; 125: 1678-85.
79. Anderson KC, Bates MP, Slaughenhoupt BL, Pinkus GS, Schlossman SF, Nadler LM. Expression of human B cell-associated antigens on leukemias and lymphomas: A model of human B cell differentiation. Blood 1984; 63: 1424-33.
80. Bubien JK, Zhou LJ, Bell PD, Frizzell RA, Tedder TF. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes. J Cell Biol 1993; 121: 1121-32.
81. Einfeld DA, Brown JP, Valentine MA, Clark EA, Ledbetter JA. Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 1988; 7: 711-7.
82. Golay JT, Clark EA, Beverley PC. The CD20 (Bp35) antigen is involved in activation of B cells from the G0 to the G1 phase of the cell cycle. J Immunol 1985; 135: 3795-801.
83. Deans JP, Kalt L, Ledbetter JA, Schieven GL, Bolen JB, Johnson P. Association of 75/80-kDa phosphoproteins and the tyrosine kinases Lyn, Fyn, and Lck with the B cell molecule CD20. Evidence against involvement of the cytoplasmic regions of CD20. J Biol Chem 1995; 270: 22632-8.
84. Cragg MS, Morgan SM, Chan HT, Morgan BP, Filatov AV, Johnson PW, et al. Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts. Blood 2003; 101: 1045-52.
85. Semac I, Palomba C, Kulangara K, Klages N, Echten-Deckert G, Borisch B, et al. Anti-CD20 therapeutic antibody rituximab modifies the functional organization of rafts/microdomains of B lymphoma cells. Cancer Res 2003; 63: 534-40.
86. Deans JP, Li H, Polyak MJ. CD20-mediated apoptosis: signalling through lipid rafts. Immunology 2002; 107: 176-82.
87. Brown DA, London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J Biol Chem 2000; 275: 17221-4.
88. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 2000; 6: 443-6.
89. Ghetie MA, Ghetie V, Vitetta ES. Anti-CD19 antibodies inhibit the function of the P-gp pump in multidrug-resistant B lymphoma cells. Clin Cancer Res 1999; 5: 3920-7.
90. Shan D, Ledbetter JA, Press OW. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies. Blood 1998; 91: 1644-52.
91. Bellosillo B, Villamor N, Lopez-Guillermo A, Marce S, Esteve J, Campo E, et al. Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species. Blood 2001; 98: 2771-7.
92. Cushman M, He HM, Katzenellenbogen JA, Lin CM, Hamel E. Synthesis, antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site. J Med Chem 1995; 38: 2041-9.
93. Huang P, Feng L, Oldham EA, Keating MJ, Plunkett W. Superoxide dismutase as a target for the selective killing of cancer cells. Nature 2000; 407: 390-5.
94. Zhou Y, Hileman EO, Plunkett W, Keating MJ, Huang P. Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents. Blood 2003; 101: 4098-104.
95. Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 2002; 100: 2187-94.
96. Anderson KC, Lust JA. Role of cytokines in multiple myeloma. Semin Hematol 1999; 36: 14-20.
97. Shimada K, Nakamura M, Ishida E, Kishi M, Konishi N. Roles of p38- and c-jun NH2-terminal kinase-mediated pathways in 2-methoxyestradiol-induced p53 induction and apoptosis. Carcinogenesis 2003; 24: 1067-75.
98. Dorr RT, Liddil JD, Klein MK, Hersh EM. Preclinical pharmacokinetics and antitumor activity of imexon. Invest New Drugs 1995; 13: 113-6.
99. Salmon SE, Kyle RA. Silicone gels, induction of plasma cell tumors, and genetic susceptibility in mice: A call for epidemiologic investigation of women with silicone breast implants. J Natl Cancer Inst 1994; 86: 1040-1.
100. Dvorakova K, Payne CM, Tome ME, Briehl MM, McClure T, Dorr RT. Induction of oxidative stress and apoptosis in myeloma cells by the aziridine-containing agent imexon. Biochem Pharmacol 2000; 60: 749-58.
101. Dvorakova K, Waltmire CN, Payne CM, Tome ME, Briehl MM, Dorr RT. Induction of mitochondrial changes in myeloma cells by imexon. Blood 2001; 97: 3544-51.
102. Dvorakova K, Payne CM, Tome ME, Briehl MM, Vasquez MA, Waltmire CN, et al. Molecular and cellular characterization of imexon-resistant RPMi8226/I myeloma cells. Mol Cancer Ther 2002; 1: 185-95.
103. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, et al. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood 1997; 89: 3354-60.
104. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, et al. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 1998; 339: 1341-8.
105. Anderson KC, Boise LH, Louie R, Waxman S. Arsenic trioxide in multiple myeloma: Rationale and future directions. Cancer J 2002; 8: 12-25.
106. Jing Y, Dai J, Chalmers-Redman RM, Tatton WG, Waxman S. Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood 1999; 94: 2102-11.
107. Grad JM, Bahlis NJ, Reis I, Oshiro MM, Dalton WS, Boise LH. Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood 2001; 98: 805-13.
108. Roussel RR, Barchowsky A. Arsenic inhibits NF-kappaB-mediated gene transcription by blocking IkappaB kinase activity and ikappaBalpha phosphorylation and degradation. Arch Biochem Biophys 2000; 377: 204-12.
109. Anderson KC, Lust JA. Role of cytokines in multiple myeloma. Semin Hematol 1999; 36: 14-20.
110. Blatt NB, Bednarski JJ, Warner RE, Leonetti F, Johnson KM, Boitano A, et al. Benzodiazepine-induced superoxide signals B cell apoptosis: Mechanistic insight and potential therapeutic utility. J Clin Invest 2002; 110: 1123-32.
111. Bednarski JJ, Warner RE, Rao T, Leonetti F, Yung R, Richardson BC, et al. Attenuation of autoimmune disease in Fas-deficient mice by treatment with a cytotoxic benzodiazepine. Arthritis Rheum 2003; 48: 757-66.
112. Alvarez D, Wiley RE, Jordana M. Cytokine therapeutics for asthma: An appraisal of current evidence and future prospects. Curr Pharm Design 2001; 7(11): 1059-81.
113. Danielsson BR, Skold AC, Azarbayjani F. Class III antiarrhythmics and phenytoin: Teratogenicity due to embryonic cardiac dysrhythmia and reoxygenation damage. Curr Pharm Design 2001; 7(9): 787-802.
114. Stewart SH, Westra HA. Benzodiazepine side-effects: From the bench to the clinic. Curr Pharm Design 2002; 8(1): 1-3.